
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1390049/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Inhaled vaccine delivery in the combat against respiratory viruses: a 2021 overview of recent developments and implications for COVID-19. Expert Review of Vaccines, 2022, 21, 957-974.	4.4	51
2	An overview of the production methods for core–shell microspheres for parenteral controlled drug delivery. European Journal of Pharmaceutics and Biopharmaceutics, 2022, 170, 24-42.	4.3	22
3	Performance of Tablet Splitters, Crushers, and Grinders in Relation to Personalised Medication with Tablets. Pharmaceutics, 2022, 14, 320.	4.5	10
4	Intradermal Administration of Influenza Vaccine with Trehalose and Pullulan-Based Dissolving Microneedle Arrays. Journal of Pharmaceutical Sciences, 2022, 111, 1070-1080.	3.3	15
5	Assessing the Immunomodulatory Effect of Size on the Uptake and Immunogenicity of Influenza- and Hepatitis B Subunit Vaccines In Vitro. Pharmaceuticals, 2022, 15, 887.	3.8	0
6	The pharmacokinetics of antibiotics in cystic fibrosis. Expert Opinion on Drug Metabolism and Toxicology, 2021, 17, 53-68.	3.3	34
7	Silencing Heat Shock Protein 47 (HSP47) in Fibrogenic Precision-Cut Lung Slices: A Surprising Lack of Effects on Fibrogenesis?. Frontiers in Medicine, 2021, 8, 607962.	2.6	8
8	Gene therapy strategies for idiopathic pulmonary fibrosis: recent advances, current challenges, and future directions. Molecular Therapy - Methods and Clinical Development, 2021, 20, 483-496.	4.1	21
9	lleo-Colon Targeting of the Poorly Water-Soluble Drug Celecoxib Using a pH-Dependent Coating in Combination with Self-Emulsifying Drug Delivery or Solid Dispersion Systems. Pharmaceutics, 2021, 13, 731.	4.5	7
10	Infliximab formulation strategy for a stable ileo-colonic targeted oral dosage form intended for the topical treatment of inflammatory bowel disease. Journal of Drug Delivery Science and Technology, 2021, 64, 102552.	3.0	3
11	Natural and bioinspired excipients for dry powder inhalation formulations. Current Opinion in Colloid and Interface Science, 2021, 56, 101497.	7.4	21
12	Microfluidic Production of Polymeric Core-Shell Microspheres for the Delayed Pulsatile Release of Bovine Serum Albumin as a Model Antigen. Pharmaceutics, 2021, 13, 1854.	4.5	5
13	Formulation and In Vitro Evaluation of Pellets Containing Sulfasalazine and Caffeine to Verify Ileo-Colonic Drug Delivery. Pharmaceutics, 2021, 13, 1985.	4.5	7
14	Nasal gene expression changes with inhaled corticosteroid treatment in asthma. Allergy: European Journal of Allergy and Clinical Immunology, 2020, 75, 191-194.	5.7	4
15	Efficacy and Safety of Peppermint Oil in a Randomized, Double-Blind Trial of Patients With Irritable Bowel Syndrome. Gastroenterology, 2020, 158, 123-136.	1.3	69
16	A comparative analysis of changes in pMDI drug dose delivery before and after detergent coating using five antistatic valved holding chambers. Journal of Allergy and Clinical Immunology: in Practice, 2020, 8, 1124-1125.e4.	3.8	13
17	Inhomogeneous Distribution of Components in Solid Protein Pharmaceuticals: Origins, Consequences, Analysis, and Resolutions. Journal of Pharmaceutical Sciences, 2020, 109, 134-153.	3.3	3
18	Dispersibility and Storage Stability Optimization of High Dose Isoniazid Dry Powder Inhalation Formulations with L-Leucine or Trileucine. Pharmaceutics, 2020, 12, 24.	4.5	29

#	Article	IF	CITATIONS
19	Reply. Journal of Allergy and Clinical Immunology: in Practice, 2020, 8, 1166-1167.	3.8	0
20	Automated Filling Equipment Allows Increase in the Maximum Dose to Be Filled in the Cyclops® High Dose Dry Powder Inhalation Device While Maintaining Dispersibility. Pharmaceutics, 2020, 12, 645.	4.5	8
21	Immunogenicity, Safety, and Efficacy of a Standalone Universal Influenza Vaccine, FLU-v, in Healthy Adults. Annals of Internal Medicine, 2020, 172, 453.	3.9	29
22	Effect of Roux-en-Y gastric bypass on the bioavailability of metoprolol from immediate and controlled release tablets: a single oral dose study before and after surgery. European Journal of Hospital Pharmacy, 2020, 27, e19-e24.	1.1	5
23	Prefilled Cyclic Olefin Sterilized Syringes of Norepinephrine Injection Solution Do Not Need to Be Stabilized by Antioxidants. AAPS PharmSciTech, 2020, 21, 247.	3.3	1
24	pH-dependent ileocolonic drug delivery, part I: in vitro and clinical evaluation of novel systems. Drug Discovery Today, 2020, 25, 1362-1373.	6.4	9
25	Review: Local Tumor Necrosis Factor-α Inhibition in Inflammatory Bowel Disease. Pharmaceutics, 2020, 12, 539.	4.5	50
26	pH-dependent ileocolonic drug delivery, part II: preclinical evaluation of novel drugs and novel excipients. Drug Discovery Today, 2020, 25, 1374-1388.	6.4	5
27	Development of an Orodispersible Film Containing Stabilized Influenza Vaccine. Pharmaceutics, 2020, 12, 245.	4.5	20
28	The Effect of Food on the Pharmacokinetics of Buspirone After Single Administration of a Sublingual Testosterone and Oral Buspirone Combination Tablet in Healthy Female Subjects. Sexual Medicine, 2020, 8, 186-194.	1.6	1
29	Eradication of Pseudomonas aeruginosa in cystic fibrosis patients with inhalation of dry powder tobramycin. Therapeutic Advances in Respiratory Disease, 2020, 14, 175346662090527.	2.6	8
30	Oromucosal films: from patient centricity to production by printing techniques. Expert Opinion on Drug Delivery, 2019, 16, 981-993.	5.0	44
31	Pharmacokinetics and tolerability of inhaled levodopa from a new dry-powder inhaler in patients with Parkinson's disease. Therapeutic Advances in Chronic Disease, 2019, 10, 204062231985761.	2.5	15
32	Development of a Stable Respiratory Syncytial Virus Pre-Fusion Protein Powder Suitable for a Core-Shell Implant with a Delayed Release in Mice: A Proof of Concept Study. Pharmaceutics, 2019, 11, 510.	4.5	1
33	Respiratory syncytial virus subunit vaccines based on the viral envelope glycoproteins intended for pregnant women and the elderly. Expert Review of Vaccines, 2019, 18, 935-950.	4.4	16
34	Towards the Oral Treatment of Ileo-Colonic Inflammatory Bowel Disease with Infliximab Tablets: Development and Validation of the Production Process. Pharmaceutics, 2019, 11, 428.	4.5	17
35	The Effect of Food on the Pharmacokinetics of Sildenafil after Single Administration of a Sublingual Testosterone and Oral Sildenafil Combination Tablet in Healthy Female Subjects. Journal of Sexual Medicine, 2019, 16, 1433-1443.	0.6	2
36	The antifibrotic potential of a sustained release formulation of a PDGFβ-receptor targeted rho kinase inhibitor. Journal of Controlled Release, 2019, 296, 250-257.	9.9	16

#	Article	IF	CITATIONS
37	Pulmonary immunization: deposition site is of minor relevance for influenza vaccination but deep lung deposition is crucial for hepatitis B vaccination. Acta Pharmaceutica Sinica B, 2019, 9, 1231-1240.	12.0	19
38	Characterization and Formulation of Isoniazid for High-Dose Dry Powder Inhalation. Pharmaceutics, 2019, 11, 233.	4.5	21
39	Associations of AMP and adenosine induced dyspnea sensation to large and small airways dysfunction in asthma. BMC Pulmonary Medicine, 2019, 19, 23.	2.0	5
40	A systematic review and meta-analysis of microbial contamination of parenteral medication prepared in a clinical versus pharmacy environment. European Journal of Clinical Pharmacology, 2019, 75, 609-617.	1.9	31
41	The effects of oxygen concentration on cell death, anti-oxidant transcription, acute inflammation, and cell proliferation in precision-cut lung slices. Scientific Reports, 2019, 9, 16239.	3.3	13
42	Development of novel zero-order release budesonide tablets for the treatment of ileo-colonic inflammatory bowel disease and comparison with formulations currently used in clinical practice. International Journal of Pharmaceutics, 2019, 554, 366-375.	5.2	25
43	Identifying critical process steps to protein stability during spray drying using a vibrating mesh or a two-fluid nozzle. European Journal of Pharmaceutical Sciences, 2019, 128, 152-157.	4.0	21
44	A gastrointestinal simulation system for dissolution of oral solid dosage forms before and after Roux-en-Y gastric bypass. European Journal of Hospital Pharmacy, 2019, 26, 152-156.	1.1	4
45	Copper-Heparin Inhalation Therapy To Repair Emphysema: A Scientific Rationale. International Journal of COPD, 2019, Volume 14, 2587-2602.	2.3	3
46	Pulmonary delivery of influenza vaccine formulations in cotton rats: site of deposition plays a minor role in the protective efficacy against clinical isolate of H1N1pdm virus. Drug Delivery, 2018, 25, 533-545.	5.7	25
47	Realising the potential of various inhaled airway challenge agents through improved delivery to the lungs. Pulmonary Pharmacology and Therapeutics, 2018, 49, 27-35.	2.6	3
48	Cross border, highly individualised treatment of a patient with challenging extensively drug-resistant tuberculosis. European Respiratory Journal, 2018, 51, 1702490.	6.7	7
49	Efficacy and Safety of On-Demand Use of 2 Treatments Designed for Different Etiologies of Female Sexual Interest/Arousal Disorder: 3 Randomized Clinical Trials. Journal of Sexual Medicine, 2018, 15, 201-216.	0.6	27
50	Bronchial Provocation Testing Can Be Improved by Using Dry Powder Adenosine Instead of Nebulized Adenosine Monophosphate. American Journal of Respiratory and Critical Care Medicine, 2018, 197, 391-394.	5.6	4
51	Pharmacokinetics of a sustained release formulation of PDGFÎ ² -receptor directed carrier proteins to target the fibrotic liver. Journal of Controlled Release, 2018, 269, 258-265.	9.9	23
52	Efficient production of solid dispersions by spray drying solutions of high solid content using a 3-fluid nozzle. European Journal of Pharmaceutics and Biopharmaceutics, 2018, 123, 50-58.	4.3	17
53	Predictors of clinical response to extrafine and non-extrafine particle inhaled corticosteroids in smokers and ex-smokers with asthma. Respiratory Research, 2018, 19, 256.	3.6	6
54	siRNA-mediated protein knockdown in precision-cut lung slices. European Journal of Pharmaceutics and Biopharmaceutics, 2018, 133, 339-348.	4.3	20

#	Article	IF	CITATIONS
55	A Novel Ileocolonic Release Peppermint Oil Capsule for Treatment of Irritable Bowel Syndrome: A Phase I Study in Healthy Volunteers. Advances in Therapy, 2018, 35, 1965-1978.	2.9	12
56	Orodispersible films based on blends of trehalose and pullulan for protein delivery. European Journal of Pharmaceutics and Biopharmaceutics, 2018, 133, 104-111.	4.3	39
57	Passive inhalation of dry powder influenza vaccine formulations completely protects chickens against H5N1 lethal viral challenge. European Journal of Pharmaceutics and Biopharmaceutics, 2018, 133, 85-95.	4.3	18
58	Advax augments B and T cell responses upon influenza vaccination via the respiratory tract and enables complete protection of mice against lethal influenza virus challenge. Journal of Controlled Release, 2018, 288, 199-211.	9.9	43
59	The mechanism behind the biphasic pulsatile drug release from physically mixed poly(dl-lactic(-co-glycolic) acid)-based compacts. International Journal of Pharmaceutics, 2018, 551, 195-202.	5.2	13
60	Ovalbumin-containing core-shell implants suitable to obtain a delayed IgG1 antibody response in support of a biphasic pulsatile release profile in mice. PLoS ONE, 2018, 13, e0202961.	2.5	6
61	The effect of formulation on spray dried Sabin inactivated polio vaccine. European Journal of Pharmaceutics and Biopharmaceutics, 2018, 129, 21-29.	4.3	9
62	Challenges for pulmonary delivery of high powder doses. International Journal of Pharmaceutics, 2018, 548, 325-336.	5.2	56
63	Development of a thermostable spray dried outer membrane vesicle pertussis vaccine for pulmonary immunization. Journal of Controlled Release, 2018, 286, 167-178.	9.9	38
64	Genotype scores predict drug efficacy in subtypes of female sexual interest/arousal disorder: A double-blind, randomized, placebo-controlled cross-over trial. Women's Health, 2018, 14, 174550651878897.	1.5	5
65	UV-Vis Spectroscopy to Enable Determination of the Dissolution Behavior of Solid Dispersions Containing Curcumin and Piperine. Journal of Young Pharmacists, 2018, 11, 26-30.	0.2	12
66	Personalized Medicine in Pediatrics: The Clinical Potential of Orodispersible Films. AAPS PharmSciTech, 2017, 18, 267-272.	3.3	56
67	How sugars protect proteins in the solid state and during drying (review): Mechanisms of stabilization in relation to stress conditions. European Journal of Pharmaceutics and Biopharmaceutics, 2017, 114, 288-295.	4.3	325
68	siRNA-Mediated RNA Interference in Precision-Cut Tissue Slices Prepared from Mouse Lung and Kidney. AAPS Journal, 2017, 19, 1855-1863.	4.4	17
69	Polymeric microspheres for the sustained release of a protein-based drug carrier targeting the PDGFβ-receptor in the fibrotic kidney. International Journal of Pharmaceutics, 2017, 534, 229-236.	5.2	21
70	Addition of Pullulan to Trehalose Glasses Improves the Stability of β-Galactosidase at High Moisture Conditions. Carbohydrate Polymers, 2017, 176, 374-380.	10.2	27
71	Developments in the formulation and delivery of spray dried vaccines. Human Vaccines and Immunotherapeutics, 2017, 13, 2364-2378.	3.3	62
72	Thermal Gradient Mid- and Far-Infrared Spectroscopy as Tools for Characterization of Protein Carbohydrate Lyophilizates. Molecular Pharmaceutics, 2017, 14, 3550-3557.	4.6	10

#	Article	IF	CITATIONS
73	Increased drug load and polymer compatibility of bilayered orodispersible films. European Journal of Pharmaceutical Sciences, 2017, 107, 183-190.	4.0	32
74	Extrafine compared to non-extrafine particle inhaled corticosteroids in smokers and ex-smokers with asthma. Respiratory Medicine, 2017, 130, 35-42.	2.9	9
75	Evaluating the immunogenicity and safety of a BiondVax-developed universal influenza vaccine (Multimeric-001) either as a standalone vaccine or as a primer to H5N1 influenza vaccine. Medicine (United States), 2017, 96, e6339.	1.0	42
76	Targeting the small airways with dry powder adenosine: a challenging concept. European Clinical Respiratory Journal, 2017, 4, 1369328.	1.5	5
77	Evaluation of the immunogenicity and safety of different doses and formulations of a broad spectrum influenza vaccine (FLU-v) developed by SEEK: study protocol for a single-center, randomized, double-blind and placebo-controlled clinical phase IIb trial. BMC Infectious Diseases, 2017, 17, 241.	2.9	30
78	Development of orodispersible films with selected Indonesian medicinal plant extracts. Journal of Herbal Medicine, 2017, 7, 37-46.	2.0	16
79	Dry powder inhalation: past, present and future. Expert Opinion on Drug Delivery, 2017, 14, 499-512.	5.0	188
80	Adjuvantation of Pulmonary-Administered Influenza Vaccine with GPI-0100 Primarily Stimulates Antibody Production and Memory B Cell Proliferation. Vaccines, 2017, 5, 19.	4.4	4
81	Prerequisites for a dry powder inhaler for children with cystic fibrosis. PLoS ONE, 2017, 12, e0183130.	2.5	15
82	Tolerability and Pharmacokinetic Evaluation of Inhaled Dry Powder Tobramycin Free Base in Non-Cystic Fibrosis Bronchiectasis Patients. PLoS ONE, 2016, 11, e0149768.	2.5	25
83	Development and potential application of an oral ColoPulse infliximab tablet with colon specific release: A feasibility study. International Journal of Pharmaceutics, 2016, 505, 175-186.	5.2	26
84	Dry influenza vaccines: towards a stable, effective and convenient alternative to conventional parenteral influenza vaccination. Expert Review of Vaccines, 2016, 15, 1431-1447.	4.4	19
85	A Design of Experiment approach to predict product and process parameters for a spray dried influenza vaccine. International Journal of Pharmaceutics, 2016, 511, 1098-1111.	5.2	55
86	Model to predict inhomogeneous protein–sugar distribution in powders prepared by spray drying. Journal of Aerosol Science, 2016, 101, 22-33.	3.8	20
87	Influence of Miscibility of Protein-Sugar Lyophilizates on Their Storage Stability. AAPS Journal, 2016, 18, 1225-1232.	4.4	37
88	Influenza Vaccine Research funded by the European Commission FP7-Health-2013-Innovation-1 project. Vaccine, 2016, 34, 5845-5854.	3.8	9
89	Pulmonary administration of small interfering RNA: The route to go?. Journal of Controlled Release, 2016, 235, 14-23.	9.9	36
90	Single dose sublingual testosterone and oral sildenafil <i>vs</i> . a dual route/dual release fixed dose combination tablet: a pharmacokinetic comparison. British Journal of Clinical Pharmacology, 2016, 81, 1091-1102.	2.4	13

#	Article	IF	CITATIONS
91	An adaptable model for growth and/or shrinkage of droplets in the respiratory tract during inhalation of aqueous particles. Journal of Aerosol Science, 2016, 93, 21-34.	3.8	15
92	Development of a zero-order sustained-release tablet containing mesalazine and budesonide intended to treat the distal gastrointestinal tract in inflammatory bowel disease. European Journal of Pharmaceutics and Biopharmaceutics, 2016, 103, 32-42.	4.3	15
93	Oromucosal film preparations: points to consider for patient centricity and manufacturing processes. Expert Opinion on Drug Delivery, 2016, 13, 493-506.	5.0	72
94	The Production of a Stable Infliximab Powder: The Evaluation of Spray and Freeze-Drying for Production. PLoS ONE, 2016, 11, e0163109.	2.5	20
95	Recent advances in the fundamental understanding of adhesive mixtures for inhalation. Current Pharmaceutical Design, 2015, 21, 5900-5914.	1.9	38
96	Gastrointestinal pH and Transit Time Profiling in Healthy Volunteers Using the IntelliCap System Confirms Ileo-Colonic Release of ColoPulse Tablets. PLoS ONE, 2015, 10, e0129076.	2.5	95
97	Can Patients with Parkinson's Disease Use Dry Powder Inhalers during Off Periods?. PLoS ONE, 2015, 10, e0132714.	2.5	13
98	Pulmonary Administration of Subunit Vaccines. Advances in Delivery Science and Technology, 2015, , 307-329.	0.4	1
99	Inulin, a flexible oligosaccharide I: Review of its physicochemical characteristics. Carbohydrate Polymers, 2015, 130, 405-419.	10.2	331
100	In-line near infrared spectroscopy during freeze-drying as a tool to measure efficiency of hydrogen bond formation between protein and sugar, predictive of protein storage stability. International Journal of Pharmaceutics, 2015, 496, 792-800.	5.2	33
101	Size and Molecular Flexibility of Sugars Determine the Storage Stability of Freeze-Dried Proteins. Molecular Pharmaceutics, 2015, 12, 684-694.	4.6	102
102	Polymeric formulations for drug release prepared by hot melt extrusion: application and characterization. Drug Discovery Today, 2015, 20, 812-823.	6.4	102
103	Production methods and stabilization strategies for polymer-based nanoparticles and microparticles for parenteral delivery of peptides and proteins. Expert Opinion on Drug Delivery, 2015, 12, 1311-1331.	5.0	39
104	Protein release from water-swellable poly(d,l-lactide-PEG)-b-poly(ϵ-caprolactone) implants. International Journal of Pharmaceutics, 2015, 480, 73-83.	5.2	8
105	Quality by design approach for optimizing the formulation and physical properties of extemporaneously prepared orodispersible films. International Journal of Pharmaceutics, 2015, 485, 70-76.	5.2	87
106	The Cyclops for pulmonary delivery of aminoglycosides; a new member of the Twincerâ"¢ family. European Journal of Pharmaceutics and Biopharmaceutics, 2015, 90, 8-15.	4.3	50
107	Can â€~extrafine' dry powder aerosols improve lung deposition?. European Journal of Pharmaceutics and Biopharmaceutics, 2015, 96, 143-151.	4.3	71
108	Comparison of adjuvants for a spray freeze-dried whole inactivated virus influenza vaccine for pulmonary administration. European Journal of Pharmaceutics and Biopharmaceutics, 2015, 93, 231-241.	4.3	16

#	Article	IF	CITATIONS
109	A levodopa dry powder inhaler for the treatment of Parkinson's disease patients in off periods. European Journal of Pharmaceutics and Biopharmaceutics, 2015, 97, 22-29.	4.3	31
110	Inulin, a flexible oligosaccharide. II: Review of its pharmaceutical applications. Carbohydrate Polymers, 2015, 134, 418-428.	10.2	123
111	Orodispersible films in individualized pharmacotherapy: The development of a formulation for pharmacy preparations. International Journal of Pharmaceutics, 2015, 478, 155-163.	5.2	78
112	Enhanced pulmonary immunization with aerosolized inactivated influenza vaccine containing delta inulin adjuvant. European Journal of Pharmaceutical Sciences, 2015, 66, 118-122.	4.0	18
113	New Mechanisms to Explain the Effects of Added Lactose Fines on the Dispersion Performance of Adhesive Mixtures for Inhalation. PLoS ONE, 2014, 9, e87825.	2.5	58
114	Effect of Inhaler Design Variables on Paediatric Use of Dry Powder Inhalers. PLoS ONE, 2014, 9, e99304.	2.5	30
115	Stability of Lysozyme in Aqueous Extremolyte Solutions during Heat Shock and Accelerated Thermal Conditions. PLoS ONE, 2014, 9, e86244.	2.5	30
116	A novel aerosol generator for homogenous distribution of powder over the lungs after pulmonary administration to small laboratory animals. European Journal of Pharmaceutics and Biopharmaceutics, 2014, 88, 1056-1063.	4.3	32
117	CARS microscopy as a tool for studying the distribution of micronised drugs in adhesive mixtures for inhalation. Journal of Raman Spectroscopy, 2014, 45, 495-500.	2.5	22
118	Technological and practical challenges of dry powder inhalers and formulations. Advanced Drug Delivery Reviews, 2014, 75, 18-31.	13.7	228
119	Improved storage stability and immunogenicity of hepatitis B vaccine after spray-freeze drying in presence of sugars. European Journal of Pharmaceutical Sciences, 2014, 55, 36-45.	4.0	50
120	NIR spectroscopy for the in-line monitoring of a multicomponent formulation during the entire freeze-drying process. Journal of Pharmaceutical and Biomedical Analysis, 2014, 97, 39-46.	2.8	27
121	A proposed definition of the â€~activity' of surface sites on lactose carriers for dry powder inhalation. European Journal of Pharmaceutical Sciences, 2014, 56, 102-104.	4.0	20
122	Evaluation of monophosphoryl lipid A as adjuvant for pulmonary delivered influenza vaccine. Journal of Controlled Release, 2014, 174, 51-62.	9.9	44
123	Simplifying Influenza Vaccination During Pandemics: Sublingual Priming and Intramuscular Boosting of Immune Responses with Heterologous Whole Inactivated Influenza Vaccine. AAPS Journal, 2014, 16, 342-349.	4.4	18
124	Pulmonary immunization of chickens using non-adjuvanted spray-freeze dried whole inactivated virus vaccine completely protects against highly pathogenic H5N1 avian influenza virus. Vaccine, 2014, 32, 6445-6450.	3.8	12
125	In vitro evaluation of the DP-4M PennCenturyâ"¢ insufflator. European Journal of Pharmaceutics and Biopharmaceutics, 2014, 88, 153-159.	4.3	35
126	Pharmacokinetics of a Prototype Formulation of Sublingual Testosterone and a Buspirone Tablet, Versus an Advanced Combination Tablet of Testosterone and Buspirone in Healthy Premenopausal Women. Drugs in R and D, 2014, 14, 125-132.	2.2	16

#	Article	IF	CITATIONS
127	Developments and strategies for inhaled antibiotic drugs in tuberculosis therapy: A critical evaluation. European Journal of Pharmaceutics and Biopharmaceutics, 2014, 86, 23-30.	4.3	54
128	Adenosine dry powder inhalation for bronchial challenge testing, part 1: Inhaler and formulation development and in vitro performance testing. European Journal of Pharmaceutics and Biopharmaceutics, 2014, 86, 105-114.	4.3	15
129	Adenosine dry powder inhalation for bronchial challenge testing, part 2: Proof of concept in asthmatic subjects. European Journal of Pharmaceutics and Biopharmaceutics, 2014, 88, 148-152.	4.3	11
130	Numerical study of agglomerate abrasion in a tumbling mixer. Chemical Engineering Science, 2014, 114, 21-29.	3.8	5
131	The clinical relevance of dry powder inhaler performance for drug delivery. Respiratory Medicine, 2014, 108, 1195-1203.	2.9	115
132	Tailored protein release from biodegradable poly(ε-caprolactone-PEG)-b-poly(ε-caprolactone) multiblock-copolymer implants. European Journal of Pharmaceutics and Biopharmaceutics, 2014, 87, 329-337.	4.3	34
133	Physical and immunogenic stability of spray freeze-dried influenza vaccine powder for pulmonary delivery: Comparison of inulin, dextran, or a mixture of dextran and trehalose as protectants. European Journal of Pharmaceutics and Biopharmaceutics, 2013, 85, 716-725.	4.3	33
134	ColoPulse tablets perform comparably in healthy volunteers and Crohn's patients and show no influence of food and time of food intake on bioavailability. Journal of Controlled Release, 2013, 172, 618-624.	9.9	23
135	Aspartate buffer and divalent metal ions affect oxytocin in aqueous solution and protect it from degradation. International Journal of Pharmaceutics, 2013, 444, 139-145.	5.2	7
136	Unraveling protein stabilization mechanisms: Vitrification and water replacement in a glass transition temperature controlled system. Biochimica Et Biophysica Acta - Proteins and Proteomics, 2013, 1834, 763-769.	2.3	122
137	Quantitative Characterization of Agglomerate Abrasion in a Tumbling Blender by Using the Stokes Number Approach. AAPS PharmSciTech, 2013, 14, 183-188.	3.3	3
138	Challenging the Two-Minute Tidal Breathing Challenge Test. Journal of Aerosol Medicine and Pulmonary Drug Delivery, 2013, 26, 380-386.	1.4	12
139	Low temperature extruded implants based on novel hydrophilic multiblock copolymer for long-term protein delivery. European Journal of Pharmaceutical Sciences, 2013, 49, 578-587.	4.0	40
140	Devices and formulations for pulmonary vaccination. Expert Opinion on Drug Delivery, 2013, 10, 1383-1397.	5.0	54
141	Nanoparticle Formulation of a Poorly Soluble Cannabinoid Receptor 1 Antagonist Improves Absorption by Rat and Human Intestine. Drug Metabolism and Disposition, 2013, 41, 1557-1565.	3.3	10
142	The Formation of Oxytocin Dimers is Suppressed by the Zinc-Aspartate-Oxytocin Complex. Journal of Pharmaceutical Sciences, 2013, 102, 1734-1741.	3.3	16
143	Mixing Time Effects on the Dispersion Performance of Adhesive Mixtures for Inhalation. PLoS ONE, 2013, 8, e69263.	2.5	16
144	Drug Content Effects on the Dispersion Performance of Adhesive Mixtures for Inhalation. PLoS ONE, 2013, 8, e71339.	2.5	26

#	Article	IF	CITATIONS
145	A User-Friendly Model for Spray Drying to Aid Pharmaceutical Product Development. PLoS ONE, 2013, 8, e74403.	2.5	20
146	Marked Endotheliotropism of Highly Pathogenic Avian Influenza Virus H5N1 following Intestinal Inoculation in Cats. Journal of Virology, 2012, 86, 1158-1165.	3.4	30
147	A New Strategy To Stabilize Oxytocin in Aqueous Solutions: II. Suppression of Cysteine-Mediated Intermolecular Reactions by a Combination of Divalent Metal Ions and Citrate. Molecular Pharmaceutics, 2012, 9, 554-562.	4.6	26
148	The Stokes Number Approach to Support Scale-Up and Technology Transfer of a Mixing Process. AAPS PharmSciTech, 2012, 13, 928-933.	3.3	3
149	Characterisation of high dose aerosols from dry powder inhalers. International Journal of Pharmaceutics, 2012, 437, 242-249.	5.2	16
150	Preparation and physicochemical evaluation of a new tacrolimus tablet formulation for sublingual administration. Drug Development and Industrial Pharmacy, 2012, 38, 490-500.	2.0	12
151	Film coated tablets (ColoPulse technology) for targeted delivery in the lower intestinal tract: Influence of the core composition on release characteristics. Pharmaceutical Development and Technology, 2012, 17, 40-47.	2.4	18
152	A density-based segmentation for 3D images, an application for X-ray micro-tomography. Analytica Chimica Acta, 2012, 725, 14-21.	5.4	12
153	Pulmonary Vaccine Delivery: A Realistic Approach?. Journal of Aerosol Medicine and Pulmonary Drug Delivery, 2012, 25, 249-260.	1.4	47
154	A Non-Invasive, Low-Cost Study Design to Determine the Release Profile of Colon Drug Delivery Systems: A Feasibility Study. Pharmaceutical Research, 2012, 29, 2070-2078.	3.5	8
155	Lactose as a carrier for inhalation products: breathing new life into an old carrier. Advanced Drug Delivery Reviews, 2012, 64, 217-219.	13.7	22
156	Kinetic energy density and agglomerate abrasion rate during blending of agglomerates into powders. European Journal of Pharmaceutical Sciences, 2012, 45, 211-215.	4.0	4
157	A statistical method for velocity detection in moving powder beds using image analysis. AICHE Journal, 2012, 58, 690-696.	3.6	4
158	Improved dissolution behavior of lipophilic drugs by solid dispersions: the production process as starting point for formulation considerations. Expert Opinion on Drug Delivery, 2011, 8, 1121-1140.	5.0	77
159	Development of a dried influenza whole inactivated virus vaccine for pulmonary immunization. Vaccine, 2011, 29, 4345-4352.	3.8	75
160	Applications of stable isotopes in clinical pharmacology. British Journal of Clinical Pharmacology, 2011, 72, 879-897.	2.4	79
161	A density based segmentation method to determine the coordination number of a particulate system. Chemical Engineering Science, 2011, 66, 6385-6392.	3.8	8
162	A New Strategy to Stabilize Oxytocin in Aqueous Solutions: I. The Effects of Divalent Metal Ions and Citrate Buffer. AAPS Journal, 2011, 13, 284-290.	4.4	27

#	Article	IF	CITATIONS
163	Bottom-Up Preparation Techniques for Nanocrystals of Lipophilic Drugs. Pharmaceutical Research, 2011, 28, 1220-1223.	3.5	83
164	CLSM as Quantitative Method to Determine the Size of Drug Crystals in a Solid Dispersion. Pharmaceutical Research, 2011, 28, 2567-2574.	3.5	5
165	Surface-Active Derivative of Inulin (Inutec® SP1) Is a Superior Carrier for Solid Dispersions with a High Drug Load. Journal of Pharmaceutical Sciences, 2011, 100, 2333-2342.	3.3	27
166	Intranasal Delivery of Influenza Subunit Vaccine Formulated with GEM Particles as an Adjuvant. AAPS Journal, 2010, 12, 109-116.	4.4	58
167	Preservation of the Immunogenicity of Dry-powder Influenza H5N1 Whole Inactivated Virus Vaccine at Elevated Storage Temperatures. AAPS Journal, 2010, 12, 215-222.	4.4	53
168	Controlled Crystallization of the Lipophilic Drug Fenofibrate During Freeze-Drying: Elucidation of the Mechanism by In-Line Raman Spectroscopy. AAPS Journal, 2010, 12, 569-575.	4.4	34
169	Prediction of the Ease of Subdivision of Scored Tablets from Their Physical Parameters. AAPS PharmSciTech, 2010, 11, 126-132.	3.3	24
170	A centrifuge method to measure particle cohesion forces to substrate surfaces: The use of a force distribution concept for data interpretation. International Journal of Pharmaceutics, 2010, 393, 89-96.	5.2	28
171	A comparison between spray drying and spray freeze drying to produce an influenza subunit vaccine powder for inhalation. Journal of Controlled Release, 2010, 144, 127-133.	9.9	154
172	Oral ileocolonic drug delivery by the colopulse-system: A bioavailability study in healthy volunteers. Journal of Controlled Release, 2010, 146, 334-340.	9.9	30
173	Gas permeation related to the moisture sorption in films of glassy hydrophilic polymers. Journal of Applied Polymer Science, 2010, 116, 3310-3317.	2.6	5
174	Blending of agglomerates into powders 1: Quantification of abrasion rate. International Journal of Pharmaceutics, 2010, 387, 87-92.	5.2	5
175	Dried influenza vaccines: Over the counter vaccines. Hum Vaccin, 2010, 6, 854-856.	2.4	4
176	Evaluation and Optimization of a Force Field for Crystalline Forms of Mannitol and Sorbitol. Journal of Physical Chemistry B, 2010, 114, 429-436.	2.6	9
177	Inulin solid dispersion technology to improve the absorption of the BCS Class IV drug TMC240. European Journal of Pharmaceutics and Biopharmaceutics, 2010, 74, 233-238.	4.3	38
178	Gastro-intestinal delivery of influenza subunit vaccine formulation adjuvanted with Gram-positive enhancer matrix (GEM) particles. European Journal of Pharmaceutics and Biopharmaceutics, 2010, 76, 470-474.	4.3	19
179	Influenza antigen-sparing by immune stimulation with Gram-positive enhancer matrix (GEM) particles. Vaccine, 2010, 28, 7963-7969.	3.8	28
180	Needle-free influenza vaccination. Lancet Infectious Diseases, The, 2010, 10, 699-711.	9.1	105

#	Article	IF	CITATIONS
181	Effect of drug-carrier interaction on the dissolution behavior of solid dispersion tablets. Pharmaceutical Development and Technology, 2010, 15, 460-468.	2.4	21
182	Changes in Performance of the Pari eFlow [®] Rapid and Pari LC Plusâ,,¢ during 6 Months Use by CF Patients. Journal of Aerosol Medicine and Pulmonary Drug Delivery, 2009, 22, 263-269.	1.4	64
183	Formulation and process development of (recombinant human) deoxyribonuclease I as a powder for inhalation. Pharmaceutical Development and Technology, 2009, 14, 358-368.	2.4	27
184	Preparation of drug nanocrystals by controlled crystallization: Application of a 3-way nozzle to prevent premature crystallization for large scale production. European Journal of Pharmaceutical Sciences, 2009, 38, 224-229.	4.0	41
185	Quantitative Image Analysis for Evaluating the Coating Thickness and Pore Distribution in Coated Small Particles. Pharmaceutical Research, 2009, 26, 965-976.	3.5	35
186	Proofâ€ofâ€concept study on the suitability of ¹³ Câ€urea as a marker substance for assessment of <i>in vivo</i> behaviour of oral colonâ€targeted dosage forms. British Journal of Pharmacology, 2009, 158, 532-540.	5.4	19
187	Development and Application of a Process Window for Achieving High-Quality Coating in a Fluidized Bed Coating Process. AAPS PharmSciTech, 2009, 10, 732-742.	3.3	5
188	Concepts for increasing gentamicin release from handmade bone cement beads. Monthly Notices of the Royal Astronomical Society: Letters, 2009, 80, 508-513.	3.3	38
189	Strongly enhanced dissolution rate of fenofibrate solid dispersion tablets by incorporation of superdisintegrants. European Journal of Pharmaceutics and Biopharmaceutics, 2009, 73, 154-161.	4.3	67
190	Comparative in vitro evaluation of four corticosteroid metered dose inhalers: Consistency of delivered dose and particle size distribution. Respiratory Medicine, 2009, 103, 1167-1173.	2.9	19
191	Efficacy of a New Pulmonary Cyclosporine A Powder Formulation for Prevention of Transplant Rejection in Rats. Journal of Heart and Lung Transplantation, 2009, 28, 486-492.	0.6	7
192	<i>In Vivo</i> Performance Testing of the Novel Medspray [®] Wet Aerosol Inhaler. Journal of Aerosol Medicine and Pulmonary Drug Delivery, 2009, 22, 317-321.	1.4	4
193	In Vitro Performance Testing of the Novel Medspray® Wet Aerosol Inhaler Based on the Principle of Rayleigh Break-up. Pharmaceutical Research, 2008, 25, 1186-1192.	3.5	22
194	Development of Stable Influenza Vaccine Powder Formulations: Challenges and Possibilities. Pharmaceutical Research, 2008, 25, 1256-1273.	3.5	171
195	Unexpected differences in dissolution behavior of tablets prepared from solid dispersions with a surfactant physically mixed or incorporated. International Journal of Pharmaceutics, 2008, 349, 66-73.	5.2	71
196	Application of process analytical technology in tablet process development using NIR spectroscopy: Blend uniformity, content uniformity and coating thickness measurements. International Journal of Pharmaceutics, 2008, 357, 108-118.	5.2	142
197	Pore Direction in Relation to Anisotropy of Mechanical Strength in a Cubic Starch Compact. AAPS PharmSciTech, 2008, 9, 528-535.	3.3	8
198	Using the Internal Stress Concept to Assess the Importance of Moisture Sorption-induced Swelling on the Moisture Transport through the Glassy HPMC Films. AAPS PharmSciTech, 2008, 9, 891-898.	3.3	4

#	Article	IF	CITATIONS
199	A novel bottom–up process to produce drug nanocrystals: Controlled crystallization during freeze-drying. Journal of Controlled Release, 2008, 128, 179-183.	9.9	143
200	Pulsatile drug delivery to ileo-colonic segments by structured incorporation of disintegrants in pH-responsive polymer coatings. Journal of Controlled Release, 2008, 132, 91-98.	9.9	74
201	Pore shape in the sodium chloride matrix of tablets after the addition of starch as a second component. European Journal of Pharmaceutics and Biopharmaceutics, 2008, 70, 539-543.	4.3	3
202	Aerosolization of Tobramycin (TOBI [®]) with the PARI LC PLUS [®] Reusable Nebulizer: Which Compressor to Use? Comparison of the CR60 [®] to the PortaNeb [®] Compressor. Journal of Aerosol Medicine and Pulmonary Drug Delivery, 2008, 21, 269-280.	1.4	18
203	The Therapeutic Index of Locally Acting Inhaled Drugs as a Function of their Fine Particle Mass and Particle Size Distribution – A Literature Review. Current Drug Delivery, 2008, 5, 142-147.	1.6	9
204	Preservation of Influenza Virosome Structure and Function During Freeze-Drying and Storage. Journal of Liposome Research, 2007, 17, 173-182.	3.3	14
205	Dry powder inhalation versus wet nebulisation delivery of antibiotics in cystic fibrosis patients. Expert Opinion on Drug Delivery, 2007, 4, 91-94.	5.0	19
206	Rational design of an influenza subunit vaccine powder with sugar glass technology: Preventing conformational changes of haemagglutinin during freezing and freeze-drying. Vaccine, 2007, 25, 6447-6457.	3.8	96
207	Pulmonary delivery of an inulin-stabilized influenza subunit vaccine prepared by spray-freeze drying induces systemic, mucosal humoral as well as cell-mediated immune responses in BALB/c mice. Vaccine, 2007, 25, 8707-8717.	3.8	135
208	Towards an oral influenza vaccine: Comparison between intragastric and intracolonic delivery of influenza subunit vaccine in a murine model. Vaccine, 2007, 26, 67-76.	3.8	26
209	Dry powder inhalation of hemin to induce heme oxygenase expression in the lung. European Journal of Pharmaceutics and Biopharmaceutics, 2007, 67, 667-675.	4.3	15
210	Dry powder inhalation of colistin in cystic fibrosis patients: A single dose pilot study. Journal of Cystic Fibrosis, 2007, 6, 284-292.	0.7	84
211	Dry powder inhalation of colistin sulphomethate in healthy volunteers: A pilot study. International Journal of Pharmaceutics, 2007, 335, 41-45.	5.2	35
212	Pore size distribution in tablets measured with a morphological sieve. International Journal of Pharmaceutics, 2007, 342, 176-183.	5.2	8
213	A novel dissolution method relevant to intestinal release behaviour and its application in the evaluation of modified release mesalazine products. European Journal of Pharmaceutical Sciences, 2007, 30, 15-20.	4.0	53
214	Inulin sugar glasses preserve the structural integrity and biological activity of influenza virosomes during freeze-drying and storage. European Journal of Pharmaceutical Sciences, 2007, 32, 33-44.	4.0	53
215	Characterization of a cyclosporine solid dispersion for inhalation. AAPS Journal, 2007, 9, E190-E199.	4.4	48
216	Design and in vitro performance testing of multiple air classifier technology in a new disposable inhaler concept (Twincer®) for high powder doses. European Journal of Pharmaceutical Sciences, 2006, 28, 171-178.	4.0	72

#	Article	IF	CITATIONS
217	Stability of influenza sub-unit vaccineDoes a couple of days outside the refrigerator matter?. Vaccine, 2006, 24, 525-531.	3.8	33
218	Air classifier technology (ACT) in dry powder inhalation. International Journal of Pharmaceutics, 2006, 310, 81-89.	5.2	38
219	Air classifier technology (ACT) in dry powder inhalation. International Journal of Pharmaceutics, 2006, 310, 72-80.	5.2	30
220	Characterization of the molecular distribution of drugs in glassy solid dispersions at the nano-meter scale, using differential scanning calorimetry and gravimetric water vapour sorption techniques. International Journal of Pharmaceutics, 2006, 310, 220-229.	5.2	135
221	The choice of a suitable oligosaccharide to prevent aggregation of PEGylated nanoparticles during freeze thawing and freeze drying. International Journal of Pharmaceutics, 2006, 311, 237-244.	5.2	98
222	The use of Stokes deformation number as a predictive tool for material exchange behaviour of granules in the â€~equilibrium phase' in high shear granulation. International Journal of Pharmaceutics, 2006, 318, 78-85.	5.2	26
223	The effect of carrier surface treatment on drug particle detachment from crystalline carriers in adhesive mixtures for inhalation. International Journal of Pharmaceutics, 2006, 327, 17-25.	5.2	53
224	The determination of relative path length as a measure for tortuosity in compacts using image analysis. European Journal of Pharmaceutical Sciences, 2006, 28, 433-440.	4.0	53
225	Characterization of the Mode of Incorporation of Lipophilic Compounds in Solid Dispersions at the Nanoscale Using Fluorescence Resonance Energy Transfer (FRET). Macromolecular Rapid Communications, 2006, 27, 1149-1155.	3.9	25
226	Positron Emission Tomography Studies of Human Airways Using an Inhaled β-Adrenoceptor Antagonist, S-11 C-CGP 12388. Chest, 2005, 128, 3020-3027.	0.8	17
227	The effect of the amount of binder liquid on the granulation mechanisms and structure of microcrystalline cellulose granules prepared by high shear granulation. International Journal of Pharmaceutics, 2005, 290, 129-136.	5.2	44
228	A critical evaluation of the relevant parameters for drug redispersion from adhesive mixtures during inhalation. International Journal of Pharmaceutics, 2005, 294, 173-184.	5.2	42
229	Spray freeze drying to produce a stable î''9-tetrahydrocannabinol containing inulin-based solid dispersion powder suitable for inhalation. European Journal of Pharmaceutical Sciences, 2005, 26, 231-240.	4.0	55
230	Inulin is a promising cryo- and lyoprotectant for PEGylated lipoplexes. Journal of Controlled Release, 2005, 103, 465-479.	9.9	65
231	The Relation Between Granule Size, Granule Stickiness, and Torque in the High-Shear Granulation Process. Pharmaceutical Research, 2005, 22, 270-275.	3.5	16
232	Location-Dependent Analysis of Porosity and Pore Direction in Tablets. Pharmaceutical Research, 2005, 22, 1399-1405.	3.5	11
233	Compaction mechanism and tablet strength of unlubricated and lubricated (silicified) microcrystalline cellulose. European Journal of Pharmaceutics and Biopharmaceutics, 2005, 59, 133-138.	4.3	75
234	The interaction between carrier rugosity and carrier payload, and its effect on drug particle redispersion from adhesive mixtures during inhalation. European Journal of Pharmaceutics and Biopharmaceutics, 2005, 59, 197-205.	4.3	39

#	Article	IF	CITATIONS
235	The effect of powder blend and tablet structure on drug release mechanisms of hydrophobic starch acetate matrix tablets. European Journal of Pharmaceutics and Biopharmaceutics, 2005, 61, 149-157.	4.3	29
236	Trends in the technology-driven development of new inhalation devices. Drug Discovery Today: Technologies, 2005, 2, 47-57.	4.0	28
237	Relative Bioavailability of Three Newly Developed Albendazole Formulations: a Randomized Crossover Study with Healthy Volunteers. Antimicrobial Agents and Chemotherapy, 2004, 48, 1051-1054.	3.2	54
238	Pharmacoeconomic review of recombinant human DNase in the management of cystic fibrosis. Expert Review of Pharmacoeconomics and Outcomes Research, 2004, 4, 49-59.	1.4	2
239	Anomalous dissolution behaviour of tablets prepared from sugar glass-based solid dispersions. Journal of Controlled Release, 2004, 97, 441-452.	9.9	74
240	Predicting mechanical properties of compacts containing two components. Powder Technology, 2004, 139, 156-164.	4.2	35
241	Solid dispersions based on inulin for the stabilisation and formulation of Δ9-tetrahydrocannabinol. European Journal of Pharmaceutical Sciences, 2004, 21, 511-518.	4.0	38
242	The role of particle engineering in relation to formulation and de-agglomeration principle in the development of a dry powder formulation for inhalation of cetrorelix. European Journal of Pharmaceutical Sciences, 2004, 23, 139-149.	4.0	58
243	The effect of vessel material on granules produced in a high-shear mixer. European Journal of Pharmaceutical Sciences, 2004, 23, 169-179.	4.0	9
244	The Mode of Drug Particle Detachment from Carrier Crystals in an Air Classifier-Based Inhaler. Pharmaceutical Research, 2004, 21, 2167-2174.	3.5	21
245	The Rate of Drug Particle Detachment from Carrier Crystals in an Air Classifier-Based Inhaler. Pharmaceutical Research, 2004, 21, 2158-2166.	3.5	18
246	Feasibility of nonvolatile buffers in capillary electrophoresis-electrospray ionization-mass spectrometry of proteins. Electrophoresis, 2004, 25, 43-49.	2.4	35
247	Incorporation of Lipophilic Drugs in Sugar Glasses by Lyophilization using a Mixture of Water and Tertiary Butyl Alcohol as Solvent. Journal of Pharmaceutical Sciences, 2004, 93, 713-725.	3.3	65
248	An investigation into the predictive value of cascade impactor results for side effects of inhaled salbutamol. International Journal of Pharmaceutics, 2004, 287, 79-87.	5.2	27
249	Which shape factor(s) best describe granules?. Powder Technology, 2004, 146, 66-72.	4.2	144
250	Effect of nebulized colistin sulphate and colistin sulphomethate on lung function in patients with cystic fibrosis: a pilot study. Journal of Cystic Fibrosis, 2004, 3, 23-28.	0.7	84
251	Dry powder inhalers for pulmonary drug delivery. Expert Opinion on Drug Delivery, 2004, 1, 67-86.	5.0	232
252	Pulmonary delivery of therapeutic peptides via dry powder inhalation: effects of micronisation and manufacturing. European Journal of Pharmaceutics and Biopharmaceutics, 2004, 58, 7-14.	4.3	67

#	Article	IF	CITATIONS
253	Investigations into the stabilization of drugs by sugar glasses: III. The influence of various high-pH buffers. Pharmaceutical Research, 2003, 20, 1437-1443.	3.5	29
254	Hollow filler-binders as excipients for direct compaction. Pharmaceutical Research, 2003, 20, 515-518.	3.5	10
255	The choice of a compressor for the aerosolisation of tobramycin (TOBI®) with the PARI LC PLUS® reusable nebuliser. International Journal of Pharmaceutics, 2003, 268, 59-69.	5.2	31
256	Potential of capillary electrophoresis for the monitoring of the stability of placental alkaline phosphatase. Journal of Pharmaceutical and Biomedical Analysis, 2003, 31, 351-357.	2.8	11
257	Drug output of unvented jet nebulizers as a function of time. International Journal of Pharmaceutics, 2003, 257, 33-39.	5.2	4
258	Investigations into the stabilisation of drugs by sugar glasses: II. International Journal of Pharmaceutics, 2003, 257, 273-281.	5.2	12
259	Air classifier technology (ACT) in dry powder inhalationPart 1. Introduction of a novel force distribution concept (FDC) explaining the performance of a basic air classifier on adhesive mixtures. International Journal of Pharmaceutics, 2003, 260, 187-200.	5.2	104
260	Air classifier technology (ACT) in dry powder inhalation Part 2. The effect of lactose carrier surface properties on the drug-to-carrier interaction in adhesive mixtures for inhalation. International Journal of Pharmaceutics, 2003, 260, 201-216.	5.2	74
261	Benefits of different drug formulations in psychopharmacology. European Neuropsychopharmacology, 2003, 13, 77-84.	0.7	15
262	The effect of carrier surface and bulk properties on drug particle detachment from crystalline lactose carrier particles during inhalation, as function of carrier payload and mixing time. European Journal of Pharmaceutics and Biopharmaceutics, 2003, 56, 291-302.	4.3	65
263	Design and Fungicidal Activity of Mucoadhesive Lactoferrin Tablets for the Treatment of Oropharyngeal Candidosis. Drug Delivery, 2002, 9, 31-38.	5.7	26
264	Breaking of scored tablets: a review. European Journal of Pharmaceutics and Biopharmaceutics, 2002, 53, 139-145.	4.3	111
265	Dry powder inhalation of antibiotics in cystic fibrosis therapy, part 1: development of a powder formulation with colistin sulfate for a special test inhaler with an air classifier as de-agglomeration principle. European Journal of Pharmaceutics and Biopharmaceutics, 2002, 54, 17-24.	4.3	42
266	Dry powder inhalation of antibiotics in cystic fibrosis therapy: part 2. European Journal of Pharmaceutics and Biopharmaceutics, 2002, 54, 25-32.	4.3	75
267	The effect of budesonide particle mass on drug particle detachment from carrier crystals in adhesive mixtures during inhalation. European Journal of Pharmaceutics and Biopharmaceutics, 2002, 54, 245-248.	4.3	21
268	Inulin as filler-binder for tablets prepared by direct compaction. European Journal of Pharmaceutical Sciences, 2002, 15, 31-38.	4.0	23
269	Pore formation in tablets compressed from binary mixtures as a result of deformation and relaxation of particles. European Journal of Pharmaceutical Sciences, 2002, 15, 171-177.	4.0	16
270	The influence of particles of a minor component on the matrix strength of sodium chloride. European Journal of Pharmaceutical Sciences, 2002, 16, 229-235.	4.0	7

#	Article	IF	CITATIONS
271	Effect of an external resistance to airflow on the inspiratory flow curve. International Journal of Pharmaceutics, 2002, 234, 257-266.	5.2	45
272	Characterization of inhalation aerosols: a critical evaluation of cascade impactor analysis and laser diffraction technique. International Journal of Pharmaceutics, 2002, 249, 219-231.	5.2	121
273	Design and application of a new modular adapter for laser diffraction characterization of inhalation aerosols. International Journal of Pharmaceutics, 2002, 249, 233-245.	5.2	41
274	Investigations into the stabilisation of drugs by sugar glasses: I. Tablets prepared from stabilised alkaline phosphatase. International Journal of Pharmaceutics, 2002, 249, 59-70.	5.2	28
275	Equivalence testing of salbutamol dry powder inhalers: in vitro impaction results versus in vivo efficacy. International Journal of Pharmaceutics, 2002, 249, 247-255.	5.2	33
276	Characterization of human placental alkaline phosphatase by activity and protein assays, capillary electrophoresis and matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. Biomedical Applications, 2001, 755, 311-319.	1.7	13
277	Inulin glasses for the stabilization of therapeutic proteins. International Journal of Pharmaceutics, 2001, 215, 163-174.	5.2	156
278	Effect of molecular weight and glass transition on relaxation and release behaviour of poly(dl-lactic) Tj ETQq0 0 0	rgBT /Ove	rlęck 10 Tf 5
279	Plasticisation of amylodextrin by moisture. Consequences for compaction behaviour and tablet properties. European Journal of Pharmaceutical Sciences, 2001, 14, 245-254.	4.0	34
280	Tensile strength of tablets containing two materials with a different compaction behaviour. International Journal of Pharmaceutics, 2000, 203, 71-79.	5.2	63
281	Plasticisation of amylodextrin by moisture. International Journal of Pharmaceutics, 2000, 204, 23-33.	5.2	29
282	A review of the technical aspects of drug nebulization. International Journal of Clinical Pharmacy, 2000, 22, 75-81.	1.4	112
283	Clinical efficacy, safety and pharmacokinetics of a newly developed controlled release morphine sulphate suppository in patients with cancer pain. European Journal of Clinical Pharmacology, 2000, 56, 219-223.	1.9	19
284	Inhalation of tobramycin in cystic fibrosis Part 1: The choice of a nebulizer. International Journal of Pharmaceutics, 1999, 189, 205-214.	5.2	41
285	Inhalation of tobramycin in cystic fibrosis Part 2: Optimization of the tobramycin solution for a jet and an ultrasonic nebulizer. International Journal of Pharmaceutics, 1999, 189, 215-225.	5.2	21
286	Can Tobramycin Inhalation Be Improved With a Jet Nebulizer?. Therapeutic Drug Monitoring, 1999, 21, 618.	2.0	22

287	Rectal absorption of morphine from controlled release suppositories. International Journal of Pharmaceutics, 1995, 114, 117-120.	5.2	8	
288	The effects of cyclodextrins on the disposition of intravenously injected drugs in the rat.	3.5	54	

The effects of cyclodextrins on the disposition of intravenously injected drugs in the rat. Pharmaceutical Research, 1991, 08, 380-384. 288

#	Article	IF	CITATIONS
289	The effect of parenterally administered cyclodextrins on cholesterol levels in the rat. Pharmaceutical Research, 1991, 08, 9-16.	3.5	133
290	The effects of cyclodextrins on drug absorption II. In vivo observations. International Journal of Pharmaceutics, 1990, 64, 195-205.	5.2	55
291	The pharmacokinetics of beta-cyclodextrin and hydroxypropyl-beta-cyclodextrin in the rat. Pharmaceutical Research, 1990, 07, 1248-1252.	3.5	95
292	Increased podophyllotoxin production in Podophyllum hexandrum cell suspension cultures after feeding coniferyl alcohol as a β-cyclodextrin complex. Plant Cell Reports, 1990, 9, 97-100.	5.6	73
293	Cyclodextrin-facilitated bioconversion of 17β-estradiol by a phenoloxidase from Mucuna pruriens cell cultures. Phytochemistry, 1990, 29, 1551-1554.	2.9	51
294	The effects of cyclodextrins on drug absorption. I. In vitro observations. International Journal of Pharmaceutics, 1989, 49, 91-102.	5.2	28
295	β-Cyclodextrin as an excipient in solid oral dosage forms: in vitro and in vivo evaluation of spray-dried diazepam-β-cyclodextrin products. International Journal of Pharmaceutics, 1989, 51, 213-223.	5.2	20
296	Determination of cyclodextrins in biological fluids by high-performance liquid chromatography with negative colorimetric detection using post-column complexation with phenolphthalein. Biomedical Applications, 1987, 415, 325-333.	1.7	50